PMID- 37073715
OWN - NLM
STAT- MEDLINE
DCOM- 20230420
LR  - 20230427
IS  - 2058-7384 (Electronic)
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 37
DP  - 2023 Jan-Dec
TI  - Identification of an immune-related genes signature to predict risk of recurrence 
      for patients with laryngeal squamous cell carcinoma.
PG  - 3946320231172075
LID - 10.1177/03946320231172075 [doi]
LID - 03946320231172075
AB  - OBJECTIVE: Numerous studies indicate that immune-related genes (IRGs) are closely 
      related to tumorigenesis and tumor progression. We aimed to establish a robust 
      IRGs-based signature to predict risk of recurrence for patients with laryngeal 
      squamous cell carcinoma (LSCC). METHODS: Gene expression profiles were acquired 
      to select differentially expressed IRGs (DEIRGs) between tumor and adjacent 
      normal tissues. Functional enrichment analysis was performed to explore the 
      biological roles of DEIRGs in LSCC. Univariate Cox analyses and LASSO regression 
      model were used to construct a IRGs-based signature with the ability to predict 
      recurrence for LSCC patients. RESULTS: A total of 272 DEIRGs were identified, of 
      which 20 DEIRGs were significantly associated with recurrence-free survival 
      (RFS). Subsequently, we constructed an eleven-IRGs signature that could classify 
      patients into high-risk or low-risk groups in TCGA-LSCC training cohort. Patients 
      in high-risk groups suffered from shorter RFS (log-rank p = 9.69E-06). Besides, 
      the recurrence rate of high-risk group was significantly higher than that of 
      low-risk group (41.1% vs. 13.7%; Fisher's exact test p < 0.001). The predictive 
      performance was validated in an independent cohort (GSE27020, log-rank p = 
      1.43E-03). Person correlation analysis showed that the risk scores calculated by 
      eleven-IRGs signature were significantly associated with filtrating immune cells. 
      Furthermore, three immune checkpoint molecules were significantly over-expressed 
      in the high-risk group. CONCLUSION: Our findings for the first time constructed a 
      robust IRGs-based signature to precisely predict risk of recurrence and further 
      provided a deeper understanding of IRGs regulatory mechanism in LSCC 
      pathogenesis.
FAU - Hong, Xiu
AU  - Hong X
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - Li, Yang
AU  - Li Y
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - Lv, Qian
AU  - Lv Q
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - An, Jun
AU  - An J
AD  - Department of Otolaryngology-Head and Neck Surgery, Xuzhou Central Hospital, 
      China. RINGGOLD: 159434
FAU - Liu, Ying
AU  - Liu Y
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - Wang, Xiuli
AU  - Wang X
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - Li, Rui
AU  - Li R
AD  - Department of Central Laboratory, Xuzhou Central Hospital, Xuzhou, China. 
      RINGGOLD: 159434
FAU - Hu, Yuqiang
AU  - Hu Y
AD  - Xuzhou Clinical School of Nanjing Medical University, Xuzhou, China. RINGGOLD: 
      12461
FAU - Liu, Bing
AU  - Liu B
AUID- ORCID: 0000-0002-7376-4234
AD  - Department of Otolaryngology-Head and Neck Surgery, Xuzhou Central Hospital, 
      China. RINGGOLD: 159434
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - *Carcinogenesis
MH  - Research Design
MH  - Risk Factors
MH  - *Head and Neck Neoplasms
MH  - Prognosis
PMC - PMC10127216
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - immune-related genes
OT  - recurrence-free survival
OT  - signature
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/04/19 06:41
MHDA- 2023/04/20 10:17
PMCR- 2023/04/19
CRDT- 2023/04/19 04:44
PHST- 2023/04/20 10:17 [medline]
PHST- 2023/04/19 06:41 [pubmed]
PHST- 2023/04/19 04:44 [entrez]
PHST- 2023/04/19 00:00 [pmc-release]
AID - 10.1177_03946320231172075 [pii]
AID - 10.1177/03946320231172075 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231172075. doi: 
      10.1177/03946320231172075.